We propose that differences in estrogen levels may contribute to the sex-specific impact of obesity on anti–PD1 efficacy, since adipose tissue is an important source of estrogens in obese males (12). The gene discussed is PDCD1; the disease is obesity due to melanocortin 4 receptor deficiency.